C-475HUntil Labs
reversible cryopreservation, vitrification, organ preservation
preservationcryonicsdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-475H
C-475HC-475Hreversible cryopreservation, vitrification, organ preservation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mutation. The study will enroll patients who meet the inclusion criteria and none of the exclusion criteria until 1000 patients are enrolled, at which point in time the study investigators will evaluate whether further patient accrual is meaningful.
This clinical trial studies whether a disposable negative pressure wound therapy (dNPWT) device, SNaP Wound Care System (Ultraportable Mechanically Powered Negative Pressure Wound Therapy) (SNaP), promotes wound healing in the lower limbs in patients that have undergone Mohs micrographic surgery (Mohs surgery) for non-melanoma skin cancer. Mohs surgery is a surgical technique used to treat skin cancer. Individual layers of cancerous tissue are removed and examined under a microscope one at a time until all cancerous tissue has been removed. It is an important part of removing skin cancer, but it often leads to soft-tissue defects and reconstructive challenges, especially in high-tension areas like the lower limbs. Typically, these wounds are managed by leaving them open and allowing them to heal from the base up or are reconstructed by transferring healthy skin from another part of the body. Negative pressure wound therapy (NPWT) is a wound dressing system that continuously or intermittently applies subatmospheric pressure to the surface of a wound to draw out fluid and promote healing. The SNaP device is a dNPWT device for lower leg wound healing designed for increased portability and ease of use outside of a hospital setting. It is a modification of traditional NPWT devices that uses springs to generate pressure, making it lighter and more user-friendly than traditional devices that rely on electrically powered pumps. This may be a more effective way to promote wound healing in the lower limbs following Mohs surgery for non-melanoma skin cancer.
What if medicine could freeze the body until treatment was available? Laura Deming explains how timing limits modern critical care when treatments are months away.
Medical hibernation raises questions beyond technology. Laura Deming, Co-founder and CEO of Until Labs, on why social continuity may be the primary factor shaping whether people choose to use it.
A talk on the intellectual history of human preservation and revival, from John Hunter's 1766 carp experiments to contemporary ideas of waiting for future advances in molecular nanotechnology. We explore the distinction between suspended animation and information preservation, why we believe aldehyde fixation makes the most sense for information preservation today, and how Sparks Brain Preservation approaches these questions. Explore more at https://sparksbrain.org/ Presented by Dr. Andrew McKenzie at Sparks Brain Preservation in Salem, OR on Dec 13, 2025. Note: Unfortunately, the recording of this talk was slightly cut off in the beginning, but it was just the first couple of slides. We're uploading it anyway because imperfection is the key to perfection. 0:00 - John Hunter's 1766 freezing experiments 0:40 - Benjamin Franklin's letter on preservation (1773) 2:02 - Could Franklin have figured it out? 3:04 - Evan Cooper: Perhaps the first cryonicist and his two revival pathways 4:2
Clip from Hunter Davis, the CSO of Until Labs, a cryopreservation startup Youtube: https://youtu.be/xaqwPd3ujHg Substack + Transcript: https://www.owlposting.com/p/bringing-organ-scale-cryopreservation Spotify: https://open.spotify.com/episode/23g2lR7dWl8NXUn893KMgv?si=5628cd0e56184130 Apple Podcasts: https://podcasts.apple.com/us/podcast/bringing-organ-scale-cryopreservation-into-existence/id1758545538?i=1000738128994
Sponsor note: the supporter of this video is rush.cloud. If you are at all involved with doing preclinical drug discovery and would benefit from computational tools, you should check out their platform + beautiful website here: rush.cloud. If you’re at all interested in working together for future episodes, reach out! ---------------------------- This is an interview with Hunter Davis, the CSO and co-founder (alongside Laura Deming) of Until Labs, which you may also know by its prior name, Cradle. They are a biotech startup devoted to organ-scale cryopreservation. They raised a $58M Series A back in September 2025, and are backed by Founders Fund (especially interesting!), Lux Ventures, and others. In this interview, we mainly talk about the engineering and scientific difficulties in the cryopreservation field, including some background details on their September 2024 progress report on neural slice rewarming, how they characterize tissue damage in their attempts to do kidney cryop
The goal of this study is to learn about of the research study drug, telomelysin (OBP-301), in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. The main question it aims to answer is whether this combination is safe and effective in this type of cancer. Participants will receive 5 injections of OBP-301, approximately every 2 weeks. OBP-301 will be injected directly into the tumor during an esophagogastroduodenoscopy (EGD). At the same time as the injection, a tumor biopsy will be taken. Participants will also receive pembrolizumab infusions every 6 weeks until disease progression or for a maximum of two years. Pembrolizumab infusions will occur on different days than OBP-301 injections.
An initial pilot and feasibility study will be conducted using a Sequential, Multiple Assignment, Randomized Trial (SMART) design to identify acceptable and effective dietary strategies to optimize both glycemic control and weight management in young adults with Type 1 diabetes (T1D). This pilot trial will include a ten-and-a-half month behavioral intervention, with co-primary outcomes of glycemic control (HbA1C and hypoglycemia) and weight loss. The pilot trial will assess acceptability and adherence to three distinct, evidence-based dietary approaches designed to address weight management and glycemic control. Behavioral counseling strategies, use of carbohydrate counting for insulin dosing, and encouragement of physical activity will be the same across the three dietary approaches. COVID-19 PROVISIONS: Due to restrictions in place on in-person visits due to COVID-19 precautions, some subjects may remain in the study longer than 10.5 months. As of June 2020, the study transitioned to a completely virtual format. Those who were due for a measurement visit during the time that research activities were halted, prior to the approval of the virtual procedures, remained on the diet they were currently assigned to, supported by bi-weekly Registered Dietitian (RD) counseling, until they were able to be scheduled for a virtual visit.
Laparotomy performed for both emergency of elective surgery may by complicated by intrabdominal collection, anastomotic leakage, infarction and others. This conditions are able to induce peritoneal inflammation. Inflamed peritoneum are able to produce excess of lactate that the investigators can measure by collecting fluid from peritoneal drainage. Drainage were left in abdomen for monitoring intrabdominal condition until the passage of stool or flatus. Minimum drainage of serum is present daily also in uncomplicated post operative period. Serum lactate relates with increased systemic anaerobic metabolism such as SIRS, sepsis and systemic hypoperfusion and it is easy to measure with a blood gas analysis. The investigators hypothesized that the increases of peritoneal/ serum lactate ratio could be an earlier, sensible, non-invasive, and economical marker of post surgical complications. The decision whether and when to perform a relaparotomy in secondary peritonitis is largely subjective and based on professional experience. Actually no existing scoring system aids in this decision. The aim of this study is to demonstrate that this ratio could be and useful tool for the surgeon in this decisional process.
The primary objective of this Study is to compare the effect of transcatheter device closure of atrial shunting to a non-closure control group over a period from cessation of procedure related medication at 3 months until 9 months post randomization by determining the proportion of patients that experience a 50% or more reduction in the baseline monthly migraine attack frequency in each group.
Objective: To study the efficacy and tolerability of mirtazapine (Remeron) in the treatment of PTSD. Research Design: This is an 8-week randomized, double-blind, placebo-controlled treatment trial of mirtazapine for the treatment of PTSD as defined on the Clinical Assessment of PTSD Scale (CAPS). Methodology: After signing an informed consent and meeting all inclusion/exclusion criteria, the patient is randomized to either mirtazapine versus placebo for 8-week duration. During the study a pharmacist maintains the randomization log and verifies the order for the placebo or mirtazapine in look-a-like tablets. Patients' symptoms, side effects and compliance are assessed bi-weekly. Based on symptomology and occurrence of side effects, the investigator increases the medication in 15 mg increments, as tolerated, until a maximum therapeutic benefit is achieved, not to exceed 45 mg/day. The dosing is at bedtime. Compliance is assessed by bi-weekly pill count at week 4 and week 8. Patients are given supportive clinical management during the clinic visits. An investigator is available by telephone 24 hrs a day in case of emergency. Patients may be seen more often if needed. Efficacy will be measured by the following assessment scales: Montgomery-Asberg Depression Rating Scale (MADRS), Hamilton Anxiety Scale (Ham-A), Clinical Global Impression Severity of Illness (CGI-s), Clinical Global Impression of Improvement (CGI-I), Global Assessment of Functioning (GAF), CAPS, Treatment Outcome PTSD rating scale (TOP-8), and Davidson Trauma Scale (DTS). Clinical Significance: Mirtazapine has shown promise in treating PTSD in an open label trial. This study is the next step in proving mirtazapine's efficacy in treatment of PTSD.
This study will use microdialysis to investigate myofascial pain. This pain is characterized by "trigger points" (exquisitely tender spots) in a group of tense muscle fibers that extend from the trigger point to the muscle attachments. Trigger points in the trapezius, a large muscle lying between the neck and shoulder, are typically caused by emotional stress, postures such as hunching shoulders, certain activities like using a telephone receiver without elbow support, or by wearing certain articles such as a heavy coat or heavy purse. Microdialysis uses a very thin needle probe (about the size and shape of an acupuncture needle) to collect and measure chemicals directly from soft tissue. Analysis of these chemicals will show whether changes in the tissue around a muscle with trigger points are confined to that muscle, or if these changes also occur in more distant muscles. The study will examine two types of trigger points. An "active" trigger point causes pain or other abnormal symptoms and often causes problems with movement. A "latent" trigger point often causes movement problems without causing pain. Many healthy adults have latent trigger points. People between 21 and 65 years of age with the following characteristics may be eligible for this study: 1) no neck pain or trigger points in either upper trapezius muscle; 2) no neck pain but a latent trigger point in at least one upper trapezius muscle; or 3) neck pain of less than 3 months' duration and an active trigger point in at least one upper trapezius muscle. Participants undergo the following procedures: * Physical examination of the muscles of the neck and shoulder area, testing strength and range of motion, and response to palpation to find trigger points. * Pain inventory. Subjects complete a questionnaire for measuring pain and its intensity, location, quality, causes, relievers, and associated symptoms. The questionnaire is filled in before and after each microdialysis procedure. * Microdialysis in upper trapezius muscle. An electrode patch is placed on either side of the site for insertion of the microdialysis probe and another electrode is placed on the outer edge of the shoulder. The electrodes are used to measure any electrical activity that occurs with insertion or movement of the probe. The subject lies face down and the probe is inserted in the upper trapezius muscle. It remains in place for 5 minutes while chemical substances are collected from the muscle. It is then advanced about 1.5 cm deeper into the muscle until a twitch response is obtained and remains in place for 10 more minutes while substances are collected. * Microdialysis in the gastrocnemius muscle (large muscle of the calf). The same procedure for the upper trapezius muscle is done in the calf muscle.
Science Isn't Complete Until It's Clear: Communication Key to Research Process - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therap … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Career Advice Science Isn’t Complete Until It’s Clear: Communication Key to Research Process November 19, 2025 | 5 min read | Manali Shah Twitter LinkedIn Facebook Email Print iStock, Eva Sanabria Communication must be viewed as more than the last step of the research process. It is the s … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Laura Deming: ‘I wanted to work on the world’s most important problem’ – The Irish Times Sections Search Sections Sections Subscribe Subscribe Close Subscribe Search Home Latest Subscriber Only Crosswords & Puzzles Show Crosswords & Puzzles sub sections The Daily Eight Crosaire Simplex Sudoku News Quiz Ireland Show Ireland sub sections Dublin Education Housing & Planning Social Affairs Stardust Politics Show Politics sub sections Poll Oireachtas Common Ground Elections & Referendums Opinion Show Opinion sub sections Editorials An Irish Diary Letters Cartoon Business Show Busine … ent to study physics at MIT, only to drop out at 17 and start a venture capital fund under the guidance of Silicon Valley entrepreneur Peter Thiel. Aubrey de Grey, the English gerontologist who has suggested that humans might live to be 1,000, calls Deming an "utter genius" for her scientific and investment "brilliance". Anti-ageing science seems to be the latest gold rush in youth-obsessed Silicon Valley. Like long-ago emperors, some tech elites are pursuing immortality thro … one can live healthier lives for longer. To that end, she founded the Longevity Fund in 2011, when she was still a teenager, to invest in biotech companies making treatments for age-related diseases. Viral content Deming suggests we think about infectious disease. “For such a long time, people viewed it as a required part of life. ‘Of course you’re going to die in your 20s or 30s from this random virus.’ You thought it was the natural course of life, until Pasteur and others … data from research firm CB Insights. Longevity VC is still a small, early-stage fund, with only $37 million in assets under management. But companies that Deming invested in when they were start-ups have now collected more than $500 million in follow-on funding from investors including Amazon chief executive Jeff Bezos and Thiel. Thiel has played a significant role in Deming's career – she was one of his elite "fellows", whom the venture capitalist pays $100,000 to drop out o … did not know what she was doing. “You’d google ‘How to start a venture capital fund’ and there were just no articles,” she says, amazed. For the first two years of the fund, Deming tried to sell investors on the “science and the humanitarian issues at stake”. “Honestly, for two years I gave the same pitch of, here’s a $20 billion market and here
Hunter Davis · Deep Tech Week / Speakers / Hunter Davis Sign in Register → Deep Tech Week · Speaker Hunter Davis Cradle Healthcare Company, Until Labs Applied Physics Healthcare Neurotech Academia Biotech Biophysics LinkedIn 01 About Hunter is a wayward physicist who’s spent his career looking for impactful problems at the intersection of physics and biology. Before becoming a founder of Cradle, he did his doctoral work in cellular magnetism with Mikhail Shapiro at Caltech before his postdoc in neuroscience with Adam Cohen at Harvard. At Cradle, Hunter leads the technical development of hibern
Instagram Instagram Log In Sign Up Close Never miss a post from tradedvc Sign up for Instagram to stay in the loop. Sign up Log in Tags _luxcapital Audio is muted tradedvc Verified • Follow San Francisco, California More options tradedvc Verified 36w Until Labs announced a $58 million Series A funding round, led by Founders Fund with participation from Lux Capital and Field Ventures, bringing its total funding to more than $100 million. Co-founded by Laura Deming and Hunter Davis, the San Francisco-based company is developing perfusion hardware, cryoprotective agents, and rewarming infrastruct … ly aiming toward whole-body medical hibernation technology. INVESTORS: Founders Fund, Lux Capital & Field Ventures ROUND: Series A AMOUNT: $58,000,000 HQ: #SanFrancisco #California #VentureCapital #UntilLabs #LauraDeming #HunterDavis #FoundersFund #LuxCapital #FieldVentures #TradedVC Load more comments No comments yet. Start the conversation. Like Comment 2 Share Save September 23, 2025 Log in to like or comment. More posts from tradedvc Carousel Clip Clip Carousel Carous
Instagram Instagram Log In Sign Up Close Never miss a post from gsa_labs Sign up for Instagram to stay in the loop. Sign up Log in gsa_labs • Follow Ivy Arts Centre More options gsa_labs 113w 🎭 TWO WEEKS UNTIL LABS 🎵 We haven’t even told you half of our acts yet, but we still can’t wait for Labs in just 2 weeks time! Tickets for this event will likely sell quickly closer to the date, so book now to avoid disappointment! Tickets are completely FREE. Don’t hesitate to get in touch if you have any questions! The GSA Labs Team 📸: @ambervanderbrugge / @ambervanderextra Load more comments emilia.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Biological Time Travel: How Cryopreservation Could Transform Medicine | Laura Deming (CEO & co-founder of Until) | The Generalist | Podwise Open in Podwise Open Prev Next 14 Oct 2025 1h 6m Biological Time Travel: How Cryopreservation Could Transform Medicine | Laura Deming (CEO & co-founder of Until) The Generalist Play Share Original Open in Podwise to generate AI notes Sign in to process this episode and unlock summaries, transcripts, highlights and translations. Open in Podwise Shownotes are not generated by Podwise. Biological Time Travel: How Cryopreservation Could Transform Medic
Laura Deming on The Generalist Podcast: Cryopreservation and Longevity | Mario Gabriele posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … hia Kenyon's pioneering longevity lab. At seventeen, she launched The Longevity Fund—one of the first venture firms dedicated to extending healthspan. Now, as co-founder of Until , she's tackling her boldest challenge: developing reversible cryopreservation. By achieving vitrification (turning tissue into glass instead of ice), Until aims to make organ preservation and medical hibernation a reality. Listen now: • YouTube: https://lnkd.in/eqgjB_CT • Spotify: https://lnkd.in/eA … k to The Angel Nest Podcast , Thorne Sparkman , Managing Director of The Slater Fund, which has long supported Rhode Island’s growing startup ecosystem. Thorne shares how new initiatives like the RI Life Science Hub are helping accelerate innovation — especially in high-impact fields such as brain therapy and technology — by connecting founders, investors, and public-private resources. #LifeSciences #Innovation #AngelInvesting #StartupEcosystem #Biotech #RhodeIsland #TheAngel
Why Cryopreservation is No Longer Science Fiction with Until Co-founder and CEO Laura Deming - No Priors: Artificial Intelligence | Technology | Startups - Podcast Episode - Podscan.fm Charts Podcast Charts Discover top podcasts and trending shows across different countries and categories. US Top Podcasts UK Top Podcasts Canada Top Podcasts Trending Now Best Podcasts by Topic View All Charts → Stats Industry Statistics Real-time insights into the global podcast ecosystem with comprehensive analytics and trends. View Industry Stats → Ideas Podscan Ideas Discover actionable business ideas extrac … ervation organ transplantation medical hibernation Until Laura Deming Longevity Fund Thiel Fellow ice formation cryoprotectant toxicity rewarming technologies scaling organs neural tissue challenges Why Cryopreservation is No Longer Science Fiction with Until Co-founder and CEO Laura Deming From No Priors: Artificial Intelligence | Technology | Startups Episode Description What if we could pause biological time to wait for a cure for a disease? Thanks to innovations and resea … s about how her time as a Thiel Fellow as well as her founding of the Longevity Fund fueled her obsession with solving the “social blindspot” of aging. Laura details how her new startup, Until, seeks to build tools that allow for “pressing pause” on biological time, starting with human organs with the hopes of scaling up to full body medical hibernation. Together, they also discuss why ice is the enemy of tissue, using engineering tools to help solve biological problems, and … y excited to be here with Laura Deming, previously the founder of the Longevity Fund, and now the co-founder and CEO of Until. We're going to talk about how until is progressing the frontier of reversible cryopreservation, or freezing, living things, and waking them back up. Beginning with human organs progressing to small animals and hopefully making progress on the whole body. 00:01:34 It sounds like science fiction, but we'll talk about some of the scientific cha … ab work you did and going to MIT and being a Teal Fellow. Like, why a longevity fund? 00:04:48 Me just being very literal. Like, at the time that I was interested in longevity, I think if you ask the average person in the field, like, what's the big problem? Most people would say, well, we just can't get enough funding for our projects.
Biological Time Travel: How Cryopreservation Could Transform Medicine (Laura Deming, CEO & co-founder of Until) - The Generalist | Podcast on Spotify
x This website requires javascript to properly function. Consider activating javascript to get access to all site functionality. LESSWRONG LW Login Bringing organ-scale cryopreservation into existence — LessWrong Biology World Optimization Frontpage 20 Bringing organ-scale cryopreservation into existence by Abhishaike Mahajan 24th Nov 2025 2 min read 0 20 I filmed a nearly-two-hour podcast with Hunter Davis , the CSO and cofounder (alongside Laura Deming ) of Until Labs , a biotech startup trying to build reversible, organ-scale cryopreservation. There’s been no shortage of podcasts on this to … do with $100M? 0 Comments 0 Biology World Optimization Frontpage 20 New Comment Submit Moderation Log More from Abhishaike Mahajan View more Curated and popular this week
Why Cryopreservation is No Lon…–No Priors: Artificial Intelligence | Technology | Startups – Apple Podcasts Search Home New Top Charts Search 29 January 31 min Why Cryopreservation is No Longer Science Fiction with Until Co-founder and CEO Laura Deming No Priors: Artificial Intelligence | Technology | Startups Play What if we could pause biological time to wait for a cure for a disease? Thanks to innovations and research in reversible cryopreservation, this possibility is no longer just science fiction. Sarah Guo sits down with Laura Deming, CEO and co-founder of biotech startup Until, to dive … s about how her time as a Thiel Fellow as well as her founding of the Longevity Fund fueled her obsession with solving the “social blindspot” of aging. Laura details how her new startup, Until, seeks to build tools that allow for “pressing pause” on biological time, starting with human organs with the hopes of scaling up to full body medical hibernation. Together, they also discuss why ice is the enemy of tissue, using engineering tools to help solve biological problems, and
Blog | until Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us ( Until science catches up to need. ) Updates From Until May 12, 2026 Rewarming Engineering Research Progress Update Scaling Reversible Cryopreservation: Engineering an Alternating Magnetic Field System for Organ-Scale Rewarming The Until Team Read more News Beyond Our Walls December 10, 2025 Laura Deming x The Generalist Podcast The Generalist Podcast September 22, 2025 Our founder, Laura Deming announces Until's Series A TBPN
How Until is Engineering Away Time in Organ Transplants | Laura Deming - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Biological Time Travel: How Cryopreservation Could Transform Medicine | Laura Deming (CEO & co-founder of Until) The Generalist Subscribe Sign in The Generalist Biological Time Travel: How Cryopreservation Could Transform Medicine (Laura Deming, CEO & co-founder of Until) 32 1 1 1× 0:00 Current time: 0:00 / Total time: -1:06:19 -1:06:19 Audio playback is not supported on your browser. Please upgrade. Biological Time Travel: How Cryopreservation Could Transform Medicine (Laura Deming, CEO & co-founder of Until) Laura Deming unpacks the science of reversible cryopreservation, the bea … hia Kenyon’s pioneering longevity lab. At seventeen, she launched The Longevity Fund—one of the first venture firms dedicated to extending human healthspan. Now, she’s tackling her boldest challenge yet: building a “pause button” for biology. As the co-founder of Until, Laura is developing reversible cryopreservation: the ability to cool living tissue to ultra-low temperatures, hold it there, and then bring it back fully functional. By achieving vitrification (the process of … ant working in the shadows ( 14:20 ) Why Laura shifted into VC at The Longevity Fund ( 17:24 ) How longevity transformed from fringe science to a legitimate field ( 19:40 ) Why Laura was driven to start Until ( 21:08 ) A simple explanation of reversible cryopreservation ( 23:10 ) Science fiction’s explorations of cryo ( 25:38 ) What sparked Laura’s interest in reversible cryo ( 27:35 ) How cryonics and reversible cryo differ, and the mechanisms behind each ( 29:00 ) Until’s r … her): https://www.generalist.com/p/antimemetics-nadia-asparouhova The Longevity Fund: https://longevity.vc/ Loyal: https://loyal.com/ H1: https://h1.co/ Until: https://www.untillabs.com/ Alcor: https://www.alcor.org/ My mental models: https://barnacles.substack.com/p/my-mental-models-2020 Subscribe to the show I’d love it if you’d subscribe and share the show. Your support makes all the difference as we try to bring more curious minds into the conversation. YouTube Spotify Ap
What's this website? + about/contact — Laura Deming Home What's this website? + about/contact Bacteria Bionumbers Beliefs / Values (old? in flux) Blog (new) Blog (posthaven archive) Laura Deming Home What's this website? + about/contact Bacteria Bionumbers Beliefs / Values (old? in flux) Blog (new) Blog (posthaven archive) What's this website? + about/contact Update as of 9/23/2025 - hi! if you’re here downstream of anything Until Labs related, feel free to email [email protected] (also goes to my main work inbox) __ Hi! This is my personal website. I like to blah unstructured thought
Cryopreservation startup lands $58m to ‘pause biological time’ Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Cortechs.ai, Microsoft part... … whole-body reversible cryopreservation. The new funding round, led by Founders Fund with participation from Lux Capital and Field Ventures, will enable Until to expand its team and infrastructure while advancing its first medical product: organ cryopreservation for transplant patients and surgeons. The company’s immediate focus is on overcoming one of transplant medicine’s most rigid bottlenecks: the narrow window of organ viability. Hearts, lungs and livers must reach recip
Lux Capital Companies People Riskgaming Mission contact Search Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. suggestions Transportation Artificial Intelligence Companies “Securities” news People A-Alpha Bio “securities” This is some text inside of a div block. About Companies People Mission riskgaming Articles, Podcasts & Scenarios More Events Media Brand Assets contact us Until is building reversible cryopreservation technology. We develop perfusion systems, cryoprotectant formulations, controlled-rate freezers, and vitrification and r
Until Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and Surgeons - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Dea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Until Labs Announces $58M Series A Funding Round, to Develop an Organ Cryopreservation Product for Transplant Patients and Surgeons September 23, 2025 | 1 min read Twitter LinkedIn Facebook Email Print This investment, led by Founders Fund with participation from Lux Capital and Field Ventures, brings tot … l Labs announced today a Series A funding round of $58 million, led by Founders Fund with participation from Lux Capital and Field Ventures. The company develops perfusion hardware, cryoprotective agents, and rewarming infrastructure to reversibly cryopreserve biological systems. The funding will be used to further grow the multidisciplinary Until team, including in chemistry, biology, mechanical engineering, electrical engineering, neuroscience, and surgery. Until is current … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
until Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us 37.0 °C What looks like a peaceful afternoon, is also a bustling molecular landscape. If you need to buy some time in a biological system, temperature is a lever. Lower it, motion slows, and metabolism stalls Ice presents the key challenge, that cryoprotectants can solve. Below –130°C, water turns to glass. We build technology to safely prevent ice formation during the vitrification process When heat returns, more afternoons like this. [ Sc
until Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us June 3, 2024 by Laura Deming & Hunter Davis Founder Letter Community A letter from Laura and Hunter Hunter's letter In 2016, my father-in-law, Mark, was diagnosed with a terminal case of mesothelioma and died months later after frontline therapies failed, as we knew they would. Near the end of his life, a Keytruda trial opened for his disease, but he was too sick to qualify. Keytruda is now recognized as an effective therapy for so
--> Until Labs Closes $58 Million in Series A top of page Menu AI & Robotics Deep Tech Fintech Security Venture Capital Other Ventures Operators' Stack Close MENLO TIMES AI & Robotics Deep Tech Fintech Security Venture Capital Other Ventures Operators' Stack More Until Labs Closes $58 Million in Series A Karan Bhatia Sep 23, 2025 1 min read Until Labs , the company developing reversible cryopreservation for patients in need of donor organs, led by Hunter Davis and Laura Deming, has secured $58 million in Series A, led by Founders Fund , with Lux Capital and Field Ventur
Bringing organ-scale cryopreservation into existence (Hunter Davis, Ep #6) Owl Posting Subscribe Sign in Playback speed × Share post Share post at current time Share from 0:00 0:00 / Transcript 14 3 3 Bringing organ-scale cryopreservation into existence (Hunter Davis, Ep #6) 1 hour and 54 minutes listening time Abhishaike Mahajan Nov 24, 2025 14 3 3 Share Transcript Sponsor note: the supporter of this video is rush.cloud . If you are at all involved with doing preclinical drug discovery and would benefit from computational tools, you should check out their platform + beautiful website here: ru … They raised a $58M Series A back in September 2025 , and are backed by Founders Fund (especially interesting!), Lux Ventures, and others. In this interview, we mainly talk about the engineering and scientific difficulties in the cryopreservation field, including some background details on their September 2024 progress report on neural slice rewarming , how they characterize tissue damage in their attempts to do kidney cryopreservation, the potential economics of future cryopr … hat’s commonly talked about and I’m happy to discuss nephrology as a particular application. But I think one thing that’s nice about vitrification is because it leverages physics instead of going after very specific biomolecular pathways, it’s somewhat organ-agnostic. Okay. Which is, I think, exceptional compared to some other chemical strategies for preservation. Abhi: Yeah. Returning back to the progress report, just because I imagine a lot of the questions, at least extern … laining about previously because this kidney is 150 grams, the same logic would apply for loading the cryoprotectant if you weren’t to use vasculature. If I were to try to load it from the outside, it would take forever. But we are perfusing through the vasculature. So I think a lot of the development that needs doing is on how do you efficiently transport cryoprotectant agents into a kidney or another organ. Abhi: How much of the... where do most of the ideas in the room usu … ecifically. I was studying it in the context of cancer hyperthermia. It was the application I was looking at. But it’s a full circle moment for me that we’ve circled back to this. So this is one thing you could think to use is alternating magnetic field heating. This is one thing that we’re studying at Until. We’re also studying some other method
Our Team | until Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us Our Team Science & Technology Roadmap Blog Careers FAQ Contact Join Us ( Our team is here for you. ) Our Team We value signal over status. Some of our team studied at top universities. Others skipped the credential ladder entirely. What unites us is proof of work: an ability to tackle hard problems with care, rigor, and speed. We promote fast when people earn it. Laura Deming CEO, Co-founder CONNECT Hunter Davis Ozawa CSO, Co-founder CONNECT Isla Weber Director of Preclinical Research CONNECT Fynn C